Research graph
References from Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction. Local targets link to admitted publications; unresolved targets remain external evidence.
Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity
10.2337/dci24-0003 · 2024 · External reference
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
10.1038/s41569-023-00849-3 · 2023 · External reference
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
10.1038/s41392-024-01931-z · 2024 · External reference
Efficacy of GLP-1 receptor agonists on weight loss, BMI, and Waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials
10.2337/dc24-1678 · 2025 · External reference
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
10.1056/nejmoa1411892 · 2015 · External reference
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
10.1038/s42255-023-00812-z · 2023 · External reference
GLP-1 physiology informs the pharmacotherapy of obesity
10.1016/j.molmet.2021.101351 · 2022 · External reference
Once-weekly semaglutide in adults with overweight or obesity
10.1056/nejmoa2032183 · 2021 · External reference
Tirzepatide once weekly for the treatment of obesity
10.1056/nejmoa2206038 · 2022 · External reference
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
10.1007/s00125-023-05973-w · 2023 · External reference
Heart failure with preserved ejection fraction
10.1056/nejmcp2305181 · 2025 · External reference
Semaglutide in patients with obesity-related heart failure and type 2 diabetes
10.1056/nejmoa2313917 · 2024 · External reference
Semaglutide in patients with heart failure with preserved ejection fraction and obesity
10.1056/nejmoa2306963 · 2023 · External reference
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
10.1016/s0140-6736(24)00469-0 · 2024 · External reference
Tirzepatide for heart failure with preserved ejection fraction and obesity
10.1056/nejmoa2410027 · 2025 · External reference
Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial
10.1016/j.jacc.2025.03.009 · 2025 · External reference
Tirzepatide REDUCES LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy
10.1016/j.jacc.2024.11.001 · 2025 · External reference
Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials
10.2337/dc25-0241 · 2025 · External reference
GLP-1 Receptor expression within the human heart
10.1210/en.2018-00004 · 2018 · External reference
GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody
10.1210/en.2013-1934 · 2014 · External reference
Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension
10.1161/atv.0000615456.97862.30 · 2020 · External reference
Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
10.1172/jci.insight.153732 · 2021 · External reference
Semaglutide reduces murine blood pressure through the vascular smooth muscle GLP-1 receptor
10.1172/jci.insight.201148 · 2026 · External reference
Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy
10.1152/ajpheart.00828.2025 · 2026 · External reference
GLP-1 and cardioprotection: from bench to bedside
10.1093/cvr/cvs123 · 2012 · External reference
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
10.1152/ajpheart.00574.2023 · 2024 · External reference
Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells
10.1038/aps.2011.149 · 2012 · External reference
GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle
10.1152/ajpendo.00283.2013 · 2014 · External reference
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride
10.1152/ajpendo.00373.2007 · 2007 · External reference
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
10.1016/j.jacc.2024.08.021 · 2024 · External reference
Inflammation in obesity-related HFpEF: the STEP-HFpEF program
10.1016/j.jacc.2024.08.028 · 2024 · External reference
Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program
10.1016/j.jacc.2024.04.022 · 2024 · External reference
Novel Gottingen miniswine model of heart failure with preserved ejection fraction integrating multiple comorbidities
10.1016/j.jacbts.2020.11.012 · 2021 · External reference
Renal denervation improves cardiac function and exercise duration in a miniswine model of heart failure with preserved ejection fraction
10.1002/ejhf.3700 · 2025 · External reference
Hydrogen sulfide deficiency and therapeutic targeting in cardiometabolic HFpEF: evidence for synergistic benefit with GLP-1/glucagon agonism
10.1016/j.jacbts.2025.04.011 · 2025 · External reference
Microvascular dysfunction in heart failure with preserved ejection fraction: pathophysiology, assessment, prevalence and prognosis
10.15420/cfr.2022.12 · 2022 · External reference
Myocardial ultrastructure of human heart failure with preserved ejection fraction
10.1038/s44161-024-00516-x · 2024 · External reference
Prognostic value of inflammatory cytokines in predicting hospital readmissions in heart failure with preserved ejection fraction
10.2147/jir.s459989 · 2024 · External reference
Immune profiling of murine cardiac leukocytes identifies triggering receptor expressed on myeloid cells 2 as a novel mediator of hypertensive heart failure
10.1093/cvr/cvad093 · 2023 · External reference
Obese-inflammatory phenotypes in heart failure with preserved ejection fraction
10.1161/circheartfailure.119.006414 · 2020 · External reference
Increased Serum levels of the notch ligand DLL1 are associated with diastolic dysfunction, reduced exercise capacity, and adverse outcome in chronic heart failure
10.1016/j.cardfail.2015.07.012 · 2016 · External reference
Elevated serum osteoprotegerin is associated with increased left ventricular mass index and myocardial stiffness
10.2459/jcm.0000000000000549 · 2017 · External reference
IL-11 is a crucial determinant of cardiovascular fibrosis
10.1038/nature24676 · 2017 · External reference
Disrupted circadian rhythmicity of the intestinal glucose transporter SGLT1 in zucker diabetic fatty rats
10.1007/s10620-013-2669-y · 2013 · External reference
The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase
10.1016/j.cmet.2018.04.015 · 2018 · External reference
Kruppel-like factor 15: regulator of BCAA metabolism and circadian protein rhythmicity
10.1016/j.phrs.2017.12.018 · 2018 · External reference
Systems biology approach uncovers candidates for liver-heart interorgan crosstalk in HFpEF
10.1161/circresaha.124.324829 · 2024 · External reference
Cardiometabolic HFpEF: NASH of the heart
10.1161/circulationaha.122.062874 · 2023 · External reference
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies
10.1111/dom.15728 · 2024 · External reference
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
10.1080/14656566.2024.2343092 · 2024 · External reference
Skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction
10.1001/jamacardio.2023.0957 · 2023 · External reference
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial
10.1016/s0140-6736(18)32261-x · 2018 · External reference
for the SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes
10.1056/nejmoa2307563 · 2023 · External reference
Premature cell senescence promotes vascular smooth muscle cell phenotypic modulation and resistance to re-differentiation
10.1093/cvr/cvaf102 · 2025 · External reference
High levels of osteoprotegerin are associated with coronary artery calcification in patients suspected of a chronic coronary syndrome
10.1038/s41598-021-98177-4 · 2021 · External reference
Osteoprotegerin regulates vascular function through syndecan-1 and NADPH oxidase-derived reactive oxygen species
10.1042/cs20210643 · 2021 · External reference
The notch ligands DLL1 and periostin are associated with symptom severity and diastolic function in dilated cardiomyopathy
10.1007/s12265-017-9748-y · 2017 · External reference
Regulation of monocyte cell fate by blood vessels mediated by notch signalling
10.1038/ncomms12597 · 2016 · External reference
Identification of conserved and tissue-restricted transcriptional profiles for lipid associated macrophages
10.1038/s42003-025-08387-z · 2025 · External reference
Single-cell gene-regulatory networks of advanced symptomatic atherosclerosis
10.1161/circresaha.123.323184 · 2024 · External reference
TREM2 as a regulator of obesity-induced cardiac remodeling: mechanisms and therapeutic insights
10.1152/ajpheart.00075.2025 · 2025 · External reference
Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure
10.1002/ehf2.15342 · 2025 · External reference
Legumain in cardiovascular diseases
10.3389/ebm.2024.10121 · 2024 · External reference
Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction
10.1038/s41419-020-03211-4 · 2020 · External reference
Catabolic defect of branched-chain amino acids promotes heart failure
10.1161/circulationaha.115.020226 · 2016 · External reference
Mitochondrial H(2)S regulates BCAA catabolism in heart failure
10.1161/circresaha.121.319817 · 2022 · External reference
Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury
10.1016/j.cmet.2016.11.005 · 2017 · External reference
Myocardial metabolomics of human heart failure with preserved ejection fraction
10.1161/circulationaha.122.061846 · 2023 · External reference
BCAA catabolism targeted therapy for heart failure with preserved ejection fraction
10.7150/thno.105894 · 2025 · External reference
Molecular signature of HFpEF: systems biology in a cardiac-centric large animal model
10.1016/j.jacbts.2021.07.004 · 2021 · External reference
Lymphatic endothelial branched-chain amino acid catabolic defects undermine cardiac lymphatic integrity and drive HFpEF
10.1161/circulationaha.124.071741 · 2025 · External reference
Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment
10.1093/eurheartj/ehaf524 · 2026 · External reference
From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited
10.1161/circresaha.121.318159 · 2021 · External reference
HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction
10.1126/scitranslmed.aay7205 · 2020 · External reference
Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism
10.1126/scitranslmed.aao0144 · 2018 · External reference
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
10.1056/nejmoa2413258 · 2025 · External reference
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis
10.1038/s41591-025-03799-0 · 2025 · External reference
Lipids and diastolic dysfunction: recent evidence and findings
10.1016/j.numecd.2022.03.003 · 2022 · External reference
Lipid use and misuse by the heart
10.1161/circresaha.116.306842 · 2016 · External reference
GLP-1 Receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function
10.1016/j.cmet.2020.05.001 · 2020 · External reference
Glucagon-like peptide-1: new regulator in lipid metabolism
10.4093/dmj.2023.0277 · 2024 · External reference
Cardiovascular risk profiles: a cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom
10.1111/dom.14580 · 2022 · External reference
A retrospective observational study examining the generalizability of glucagon-like peptide 1 receptor agonist cardiovascular outcome trials to the real-world population with type 2 diabetes in Spain: the REPRESENT study
10.1007/s12325-022-02196-0 · 2022 · External reference
Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
10.1056/nejmoa1509225 · 2015 · External reference
Liraglutide and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1603827 · 2016 · External reference
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
10.1056/nejmoa1607141 · 2016 · External reference
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
10.1056/nejmoa1901118 · 2019 · External reference
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
10.1056/nejmoa2108269 · 2021 · External reference
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
10.1111/dom.13649 · 2019 · External reference
Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials
10.1016/j.jdiacomp.2014.01.009 · 2014 · External reference
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks
10.2337/dc09-1914 · 2010 · External reference
Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: a narrative review
10.1016/j.jdiacomp.2022.108390 · 2023 · External reference
Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral artery disease: the STARDUST randomized clinical trial
10.1001/jamanetworkopen.2024.1545 · 2024 · External reference
